Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture
21.7.2021 11:00:00 EEST | Business Wire | Press release
Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics （Apeiron）, a Shanghai based company focused on novel oncology drugs, announced today a strategic research and development collaboration agreement. The collaboration will leverage the patient-centric AI-first capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. All pipeline products will be equally owned and Exscientia holds an equity stake in Apeiron.
This expanded collaboration follows the successful design of multiple selective CDK7 compounds. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.
“Based on what they have already achieved, Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far,” stated Dr. Mingxi Li, President of GT Apeiron Therapeutics. “We have been incredibly impressed by the combined power of the AI design and use of patient data to optimize and select molecules that are more likely to give positive effects in the clinic. This joint venture is a significant step in building GT Apeiron’s valuable and robust pipeline of CDK inhibitor drugs and substantially accelerates our early-stage output and progression towards being a clinical stage biotech company.”
“We are driven to bring drugs to market that make a difference for patients,” says Andrew Hopkins, chief executive officer of Exscientia. “Apeiron bring a focus and an expertise on the biological basis of multiple cancers and helps us to create better drugs for better outcomes in the clinic and beyond. This collaboration has already proven to be capable of delivering potential drug candidates with promising patient-relevant data, and we look forward to extending that into a portfolio of multiple clinical assets.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai Social media: Twitter @exscientiaAI. LinkedIn https://www.linkedin.com/company/ex-scientia/
About GT Apeiron Therapeutics
GT Apeiron Therapeutics is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs. To learn more, visit http://www.apeiron-bio.com/ Social media: LinkedIn https://www.linkedin.com/company/gt-apeiron-therapeutics/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005394/en/
Contact information
Exscientia Enquiries:
Edelman PR
Nathan Field
P: +44 (0)7866 411198
Nathan.Field@edelman.com
GT Apeiron Therapeutics Contact:
info@apeiron-bio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Airship Announces Next-Generation AI Capabilities to Deliver the Right Customer Experience in the Moment27.10.2026 15:00:00 EET | Press release
Airship, the mobile-first customer experience company, today introduced new capabilities that activate customer insights and real-time context through a single platform. Building on its breakthrough Airship Decisioning AI for modern mobile platforms like iOS 27, Airship helps enterprise brands understand customer behavior in the moment and deliver personalized mobile interactions that drive conversion and revenue. Customer expectations for tailored experiences are compounding, and legacy platforms struggle to keep pace. Research from Deloitte and Meta states that “80% of U.S. consumers are more likely to purchase from brands offering personalized experiences,” but many organizations fail to meet those expectations due to siloed data, disconnected systems, and developer dependencies. Modern customer experience requires fully understanding who a customer is and what they need in real time. Airship Decisioning AI pairs customer profile data with real-time context right on the user’s devic
NTT DATA Expands AI Factory Footprint Globally to Help Clients Scale AI from Pilots to Production27.10.2026 15:00:00 EET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the global expansion of NTT DATA AI Factories, which provide hands-on environments where organizations can determine how priority AI use cases can be deployed, secured, governed and operated at scale. The environments help business and technology leaders evaluate AI workloads against real-world requirements including infrastructure architecture, performance, workload placement and cost. NTT DATA’s market research shows enterprise leaders want greater confidence about performance and business value before scaling AI investments. For many organizations, the shift from AI pilots to production is stalled by infrastructure bottlenecks, governance concerns, security requirements and uncertainty around operational costs and performance. To help clients make deployment decisions with greater confidence, NTT DATA AI Factories bring together the company’s full-stack AI capabilities with technologies from l
Europe's Largest Halloween Festival Marks 40 Years in the Birthplace of Halloween27.10.2026 14:37:00 EET | Press release
Rooted in the ancient Celtic festival of Samhain, which marked the end of the harvest season and the beginning of winter more than 2,000 years ago, Halloween can trace its origins to Ireland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020759137/en/ Derry Halloween, Co. Derry~Londonderry This year, the story comes full circle as Derry Halloween, Europe's oldest and largest Halloween festival, celebrates its 40th anniversary, leading a programme of events across the island that blend history, storytelling, music, food and spectacle. Derry Halloween began organically as a community celebration in 1985, when a Halloween fancy-dress party in a local pub was evacuated during a security alert at the height of the Troubles, sending revellers onto the streets and sparking a tradition that would grow into Europe's largest Halloween festival. Four decades on, the event reflects the city's remarkable journey from conflict to peac
Effort Inflation Puts Brand Loyalty at Risk, Netcracker/CSG Research Finds27.10.2026 14:30:00 EET | Press release
Netcracker/CSG® today released the 2027 State of the Customer Experience Report, which finds that “Effort Inflation,” the growing time, steps, and mental effort customers must use to engage with brands, is damaging trust and loyalty. The findings show that customers will stay with brands that make touchpoints faster and easier, ensure continuity across channels, and preserve access to human support when needed. One consequence of Effort Inflation is the rise of a “shadow customer experience” layer, where customers turn to third-party AI assistants and personal agents to navigate brand interactions, pushing critical touchpoints out of the brand’s control. As more support journeys shift outside owned channels, brands risk losing visibility, context, and opportunities to build trust. This trend reinforces the need for connected, effortless experiences that maintain context across channels, resolve issues quickly, and strengthen loyalty. Netcracker/CSG’s global survey of 1,800 digital citi
AHS Properties to Launch USD 1.3 Billion AHS Twin Towers, a Grade A Commercial Office Building on Sheikh Zayed Road27.10.2026 14:17:00 EET | Press release
AHS Properties is set to launch AHS Twin Towers, its new commercial development on Sheikh Zayed Road, following the AED 1.1 billion acquisition of Shangri-La Dubai. The property will undergo a major transformation into a Grade A commercial destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027110920/en/ Abbas Sajwani, Founder and CEO of AHS Properties (Photo: AETOSWire) Positioned on one of Dubai’s most prominent commercial corridors, AHS Twin Towers will introduce a new architectural identity for the property. The project has been designed by Gensler, an internationally recognised architecture and design firm, with interiors by AHS Atelier, the company’s in-house design studio, bringing a bespoke approach to materiality, detailing and craftsmanship throughout the development. AHS Twin Towers will comprise ground floor plus 50. The development will offer flexible Grade A office environments supported by an integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom